Instead of setting a New Year's resolution, columnist Susan Payrovi, MD, chooses an intention to guide her as she navigates ...
The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) has cleared Pheno Therapeutics to initiate a first-in-human Phase 1 clinical trial to test its oral candidate PTD802 in ...
Pheno Therapeutics has gained clinical trial authorisation (CTA) from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for its small molecule therapeutic, PTD802. The ...
A selective GPR17 (G protein-coupled receptor 17) antagonist, PTD802 is a novel small molecule therapeutic designed to promote remyelination. Developed under an exclusive worldwide licence ...
Fraser Murray, PhD, CEO, Pheno Therapeutics. Image Credit: Pheno Therapeutics A selective GPR17 (G protein-coupled receptor 17) antagonist, PTD802 is a novel small molecule therapeutic designed to ...
PTD802 is aimed at promoting remyelination in individuals with neurological conditions, particularly multiple sclerosis. Credit: New Africa/Shutterstock. Pheno Therapeutics has gained clinical trial ...
A selective GPR17 (G protein-coupled receptor 17) antagonist, PTD802 is a novel small molecule therapeutic designed to promote remyelination. Developed under an exclusive worldwide licence agreement ...
EDINBURGH, Scotland, January 14, 2025--(BUSINESS WIRE)--Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback